Skip to main content

Is My Product Recalled?

Food Recalls Medication Recalls Baby Products Pet Products Toys Electronics Household Vehicles Medical Devices Other

Scan How It Works Saved Get Alerts

Menu

Search All Recalls Latest Recalls Scan Barcode Get Alerts

Categories

Food Recalls Medication Recalls Baby Products Pet Products Toys Electronics Household Vehicles Medical Devices Other

Resources

How Recalls Work FAQ Recall Classifications Statistics & Trends About

Your Recalls

Loading...

Stay Informed

Get email alerts when new recalls match your interests.

Recall data is updated hourly from official government sources. Very recent recalls may not yet appear. About our data sources

About

We make U.S. recall data searchable and accessible for consumers and businesses.

Site

FAQ
Browse by State
Statistics
Recall Classifications
About
Enterprise API

Legal

Privacy Policy
Terms of Service
Report Incorrect Info

Official Sources

FDA Recalls ↗
USDA FSIS ↗
CPSC Recalls ↗
NHTSA Recalls ↗

Home
/
Brands
/
Torrent Pharma Inc.

Torrent Pharma Inc. Recalls

All product recalls associated with Torrent Pharma Inc..

Get alerts for this brand

Recall Summary

Total Recalls

35

Past Year

2

Class I (Serious)

0

Most Recent

May 2025

Data from FDA, USDA, CPSC, and NHTSA public records. Recall counts vary by company size, industry, and reporting practices. Always check official sources for current information.

Showing 1–20 of 35 recalls

Fluoxetine Tablets (Torrent Pharma) - CGMP Nitrosamine Deviation (2025)

CGMP Deviations: Presence of N-Nitroso Fluoxetine exceeding interim acceptable intake limit.

Class IIModerate

FDAMay 27, 2025Nationwide• Torrent Pharma Inc.

Fluoxetine Tablets (Torrent Pharma) - CGMP Nitrosamine Deviation (2025)

CGMP Deviations: Presence of N-Nitroso Fluoxetine exceeding interim acceptable intake limit.

Class IIModerate

FDAMay 27, 2025Nationwide• Torrent Pharma Inc.

Losartan Potassium Tablets 50mg (Torrent) – NMBA Impurity (2019)

CGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobutyric acid (NMBA) in the finished product above the interim acceptable daily intake level of 9.82 parts per million.

Previous

12

Page 1 of 2Next

Class IIModerate

FDASep 19, 2019Nationwide• Torrent Pharma Inc.

Losartan/Hydrochlorothiazide Tablets 100mg (Torrent) – NMBA Impurity (2019)

CGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobutyric acid (NMBA) in the finished product above the interim acceptable daily intake level of 9.82 parts per million.

Class IIModerate

FDASep 19, 2019Nationwide• Torrent Pharma Inc.

Losartan/Hydrochlorothiazide Tablets 50mg (Torrent) – NMBA Impurity (2019)

CGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobutyric acid (NMBA) in the finished product above the interim acceptable daily intake level of 9.82 parts per million.

Class IIModerate

FDASep 19, 2019Nationwide• Torrent Pharma Inc.

Losartan Potassium Tablets 100mg (Torrent) – NMBA Impurity (2019)

CGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobutyric acid (NMBA) in the finished product above the interim acceptable daily intake level of 9.82 parts per million.

Class IIModerate

FDASep 19, 2019Nationwide• Torrent Pharma Inc.

Losartan Potassium Tablet (Torrent Pharma) – Impurity Detection (2019)

CGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobutyric acid (NMBA) in the finished product above the interim acceptable daily intake level.

Class IIModerate

FDAApr 18, 2019Nationwide• Torrent Pharma Inc.

Losartan/Hydrochlorothiazide Tablet (Torrent Pharma) – Impurity Detection (2019)

CGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobutyric acid (NMBA) in the finished product above the interim acceptable daily intake level.

Class IIModerate

FDAApr 18, 2019Nationwide• Torrent Pharma Inc.

Losartan Potassium Tablet (Torrent Pharma) – Impurity Detection (2019)

CGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobutyric acid (NMBA) in the finished product above the interim acceptable daily intake level.

Class IIModerate

FDAApr 18, 2019Nationwide• Torrent Pharma Inc.

Losartan Potassium Tablet (Torrent Pharma) – Impurity Detection (2019)

CGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobutyric acid (NMBA) in the finished product above the interim acceptable daily intake level.

Class IIModerate

FDAApr 18, 2019Nationwide• Torrent Pharma Inc.

Losartan Hydrochlorothiazide Tablets (Torrent Pharma) – NMBA Impurity (2019)

CGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobutyric acid (NMBA) in the finished product above the interim acceptable daily intake level.

Class IIModerate

FDAApr 18, 2019Nationwide• Torrent Pharma Inc.

Losartan Potassium Tablets (Torrent Pharma) – NMBA Impurity (2019)

CGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobutyric acid (NMBA) in the finished product above the interim acceptable daily intake level.

Class IIModerate

FDAApr 18, 2019Nationwide• Torrent Pharma Inc.

Losartan Hydrochlorothiazide Tablets (Torrent) – Impurity Risk (2019)

CGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobutyric acid (NMBA) in the finished product above the interim acceptable daily intake level.

Class IIModerate

FDAFeb 28, 2019Nationwide• Torrent Pharma Inc.

Losartan Hydrochlorothiazide Tablets (Torrent) – Impurity Risk (2019)

CGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobutyric acid (NMBA) in the finished product above the interim acceptable daily intake level.

Class IIModerate

FDAFeb 28, 2019Nationwide• Torrent Pharma Inc.

Losartan Potassium Tablets (Torrent) – Impurity Risk (2019)

CGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobutyric acid (NMBA) in the finished product above the interim acceptable daily intake level.

Class IIModerate

FDAFeb 28, 2019Nationwide• Torrent Pharma Inc.

Losartan Potassium Tablets (Torrent) – Impurity Risk (2019)

CGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobutyric acid (NMBA) in the finished product above the interim acceptable daily intake level.

Class IIModerate

FDAFeb 28, 2019Nationwide• Torrent Pharma Inc.

Losartan Potassium Tablets (Torrent) – Impurity Risk (2019)

CGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobutyric acid (NMBA) in the finished product above the interim acceptable daily intake level.

Class IIModerate

FDAFeb 28, 2019Nationwide• Torrent Pharma Inc.

Losartan Potassium Tablets (Torrent Pharma) – NMBA Impurity (2019)

CGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobutyric acid (NMBA) in the finished product above the interim acceptable daily intake level.

Class IIModerate

FDAFeb 28, 2019Nationwide• Torrent Pharma Inc.

Losartan Hydrochlorothiazide Tablets (Torrent) – NDEA Impurity (2018)

CGMP Deviations: FDA lab confirmed presence an impurity, N-nitrosodimethylamine (NDEA) contained in the API used to manufacture the product above the interim acceptable daily intake level of 0.083 parts per million.

Class IIModerate

FDADec 20, 2018Nationwide• Torrent Pharma Inc.

Losartan Potassium Tablets (Torrent) – NDEA Impurity (2018)

CGMP Deviations: FDA lab confirmed presence an impurity, N-nitrosodimethylamine (NDEA) contained in the API used to manufacture the product above the interim acceptable daily intake level of 0.083 parts per million.

Class IIModerate

FDADec 20, 2018Nationwide• Torrent Pharma Inc.